Developer docs
API playgroundTry for free, no card

Search company profiles

Atlas Venture

Full company profile

uuid00008mb

Namestring
Atlas Venture
Legal namestring
Atlas Venture
Company typeenum
Private
Founded yearint
1992
Descriptiontext

Atlas Venture is a Cambridge, Massachusetts-based venture capital firm that creates and builds early-stage biotechnology companies. Founded originally in the 1980s and repositioned around life sciences in the early 1990s, the firm operates a company-creation model in which partners and Entrepreneurs-in-Residence identify transformative scientific innovation, spin out new entities, and serve as long-term operating partners from formation through commercialization. Over more than 30 years the firm has launched 92 startups from its incubator, with portfolio companies producing 25+ medicines, 43 IPOs, and 39 M&A exits.

The firm manages multiple venture funds, with the most recent disclosed vehicles being the $300 million Second Opportunity Fund (October 2021), the $450 million Fund XIII (March 2022), and the $400 million Third Opportunity Fund (September 2025), alongside legacy Funds VI through XIV and AVOF I through III. Atlas's core products are (1) venture capital investment services across seed through growth stages, (2) company creation and incubation through the EIR program, and (3) the Nautilus leadership community, Compass startup playbook, and Investor Reporting Portal platforms that provide portfolio operations support. The investment team includes six active partners (David Grayzel, Bruce Booth, Jean-François Formela, Jason Rhodes, Kevin Bitterman, and Michael Gladstone), three principals, four senior associates, and an extensive bench of venture partners, EIRs, and Atlas Advisors composed of former pharma R&D leaders and biotech CEOs.

Atlas Venture earns revenue through standard venture capital mechanics: management fees on committed fund capital and carried interest on realized exits from portfolio company IPOs (such as Kailera Therapeutics' $625 million Nasdaq offering in April 2026) and M&A transactions. Customers are two-sided: institutional limited partners supplying fund capital, and life-science entrepreneurs and scientists receiving company-formation capital, operating support, and ecosystem access. Geographic focus is the U.S. Northeast with select international portfolio exposure (e.g., Italy-based AAVantgarde Bio).

Short descriptiontext

Atlas Venture is a Cambridge-based early-stage venture capital firm that creates and builds biotechnology companies through a seed-led incubator model, partnering with entrepreneurs-in-residence to spin out therapeutics startups across autoimmune, oncology, metabolic, and rare disease indications for institutional limited partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life sciences venture capital, biotech startup creation, seed stage investing, company incubation, portfolio management
Industry2 codes
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYBPAHADAC
M&A Advisory (Buy-side/Sell-side)
NAICS code4 codes
  • Portfolio Management and Investment Advice523940
  • Portfolio Management and Investment Advice52394
  • All Other Financial Investment Activities52399
  • Miscellaneous Financial Investment Activities523999
SIC code2 codes
  • Investment Advice6282
  • Investors, Nec6799
Product category
Life Sciences Venture Capital
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Fund Management
TypeLicensing Royalties
Description

Atlas Venture manages multiple venture funds (X, XI, XII, XIII, XIV, AVOF I, II, III, and legacy funds VI, VII, VIII, IX) and generates revenue through management fees and carried interest from portfolio company exits.

atlasventure.com
2Portfolio Company Equity
TypeTransaction Fee
Description

Returns generated through equity stakes in portfolio companies, including IPOs and M&A exits such as 43 IPOs and 39 M&A exits historically.

atlasventure.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Atlas Venture is a life sciences venture capital firm that creates, incubates, and invests in early-stage biotechnology companies through multiple dedicated funds. The firm partners shoulder-to-shoulder with Entrepreneurs-In-Residence and operators to build platform and product companies, providing capital, strategic guidance, and operational resources from seed through commercialization, and generating returns via management fees, carried interest, and equity stakes in portfolio exits.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 25+ medicines developed by portfolio companies
+3 more records
Product overview1 text field

Atlas Venture is a venture capital firm that builds breakthrough biotechnology companies through a seed-led investment model. The firm operates as a company creation platform, partnering with entrepreneurs-in-residence to identify transformative science and build new ventures. Atlas provides funding vehicles (multiple fund generations including Funds X through XIV, AVOF I, II, III, and Opportunity Funds), strategic resources through its Nautilus community platform for portfolio leadership, and Compass as a company-building playbook. The firm has launched 92 startups, achieved 43 IPOs, and 39 M&A exits, with over 25 medicines made by portfolio companies.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Flagship Pioneering is a direct peer - a Cambridge-based biotech company creation platform that builds breakthrough life sciences ventures from inception using an "origination" model closely analogous to Atlas's incubator approach. Both firms operate scientist-EIR partnerships to launch new biotech companies rather than purely funding external teams.

TypeDirect peer
Description

Third Rock Ventures is a direct peer - a Boston-based venture firm that builds biotech companies from inception by partnering with entrepreneurs and scientists, mirroring Atlas's seed-led company creation model. Both firms focus on launching and operating new biotech ventures rather than just providing capital.

TypeDirect peer
Description

ARCH Venture Partners is a direct peer - one of the largest early-stage biotech VCs that co-invests alongside Atlas in deals like Kailera Therapeutics and nChroma Bio, with a comparable focus on creating companies from breakthrough university and biotech research.

TypeDirect peer
Description

Versant Ventures is a direct peer - a healthcare-focused VC that builds biotech companies through in-house incubation (e.g., Inception Sciences) similar to Atlas's EIR-driven model, investing across multiple fund vintages with comparable life sciences focus.

TypeDirect peer
Description

5AM Ventures is a direct peer - an early-stage life sciences VC firm with a hands-on company creation approach that has operated comparable fund vintages and portfolio strategies to Atlas, often co-investing in seed and Series A biotech rounds.

TypeDirect peer
Description

OrbiMed is a direct peer - one of the largest healthcare-dedicated investment firms globally, participating in many of the same rounds as Atlas (Q32 Bio, etc.) with a broader life sciences mandate spanning venture, growth, and public equities.

TypeDirect peer
Description

RA Capital Management is a direct peer - a healthcare-focused crossover fund that co-leads many of Atlas's portfolio financings (Kinaset, TRIANA, Q32 Bio), offering a complementary late-stage and public-equity capability that overlaps with Atlas's biotech investing universe.

TypeBroad incumbent
Description

NEA is a broad incumbent - a large multi-stage venture firm with a significant healthcare and biotech practice that competes for similar deals and LPs, though its broader tech focus makes it less specialized than Atlas in biotech venture creation.

TypeDirect peer
Description

Foresite Capital is a direct peer - a healthcare and biotech-focused investment firm that has co-invested with Atlas and operates comparable fund vintages targeting therapeutic and biomedical innovation, often overlapping in syndicate participation.

TypeDirect peer
Description

Apple Tree Partners is a direct peer - a biotech-focused venture firm that builds companies through internal incubation, comparable to Atlas's model, and competes for similar life sciences talent and deal flow in the Northeast US ecosystem.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles23 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment682 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Atlas Venture

Life Sciences Venture Capitalatlasventure.com

Atlas Venture is a Cambridge-based early-stage venture capital firm that creates and builds biotechnology companies through a seed-led incubator model, partnering with entrepreneurs-in-residence to spin out therapeutics startups across autoimmune, oncology, metabolic, and rare disease indications for institutional limited partners.

What Atlas Venture does

Atlas Venture is a Cambridge, Massachusetts-based venture capital firm that creates and builds early-stage biotechnology companies. Founded originally in the 1980s and repositioned around life sciences in the early 1990s, the firm operates a company-creation model in which partners and Entrepreneurs-in-Residence identify transformative scientific innovation, spin out new entities, and serve as long-term operating partners from formation through commercialization. Over more than 30 years the firm has launched 92 startups from its incubator, with portfolio companies producing 25+ medicines, 43 IPOs, and 39 M&A exits.

The firm manages multiple venture funds, with the most recent disclosed vehicles being the $300 million Second Opportunity Fund (October 2021), the $450 million Fund XIII (March 2022), and the $400 million Third Opportunity Fund (September 2025), alongside legacy Funds VI through XIV and AVOF I through III. Atlas's core products are (1) venture capital investment services across seed through growth stages, (2) company creation and incubation through the EIR program, and (3) the Nautilus leadership community, Compass startup playbook, and Investor Reporting Portal platforms that provide portfolio operations support. The investment team includes six active partners (David Grayzel, Bruce Booth, Jean-François Formela, Jason Rhodes, Kevin Bitterman, and Michael Gladstone), three principals, four senior associates, and an extensive bench of venture partners, EIRs, and Atlas Advisors composed of former pharma R&D leaders and biotech CEOs.

Atlas Venture earns revenue through standard venture capital mechanics: management fees on committed fund capital and carried interest on realized exits from portfolio company IPOs (such as Kailera Therapeutics' $625 million Nasdaq offering in April 2026) and M&A transactions. Customers are two-sided: institutional limited partners supplying fund capital, and life-science entrepreneurs and scientists receiving company-formation capital, operating support, and ecosystem access. Geographic focus is the U.S. Northeast with select international portfolio exposure (e.g., Italy-based AAVantgarde Bio).

Atlas Venture firmographics

Firmographics
Name
Atlas Venture
Legal name
Atlas Venture
Website
https://atlasventure.com
Company type
Private
Founded year
1992
Operating status
Operating
Headcount range
101–250 employees
Short description
Atlas Venture is a Cambridge-based early-stage venture capital firm that creates and builds biotechnology companies through a seed-led incubator model, partnering with entrepreneurs-in-residence to spin out therapeutics startups across autoimmune, oncology, metabolic, and rare disease indications for institutional limited partners.
Ownership category
akta.pro rank

Atlas Venture industry classification

Industry
Product category
Life Sciences Venture Capital
NAICS
Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394), All Other Financial Investment Activities (52399), Miscellaneous Financial Investment Activities (523999)
SIC
Investment Advice (6282), Investors, Nec (6799)
akta.pro industry
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYBPAHADAC
M&A Advisory (Buy-side/Sell-side)

Keywords

  • Life sciences venture capital
  • Biotech startup creation
  • Seed stage investing
  • Company incubation
  • Portfolio management

Where Atlas Venture is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Atlas Venture business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Fund Management: Atlas Venture manages multiple venture funds (X, XI, XII, XIII, XIV, AVOF I, II, III, and legacy funds VI, VII, VIII, IX) and generates revenue through management fees and carried interest from portfolio company exits.
  2. Portfolio Company Equity: Returns generated through equity stakes in portfolio companies, including IPOs and M&A exits such as 43 IPOs and 39 M&A exits historically.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Atlas Venture product offering

Product offering

Core offering

Atlas Venture is a life sciences venture capital firm that creates, incubates, and invests in early-stage biotechnology companies through multiple dedicated funds. The firm partners shoulder-to-shoulder with Entrepreneurs-In-Residence and operators to build platform and product companies, providing capital, strategic guidance, and operational resources from seed through commercialization, and generating returns via management fees, carried interest, and equity stakes in portfolio exits.

Product overview

Atlas Venture is a venture capital firm that builds breakthrough biotechnology companies through a seed-led investment model. The firm operates as a company creation platform, partnering with entrepreneurs-in-residence to identify transformative science and build new ventures. Atlas provides funding vehicles (multiple fund generations including Funds X through XIV, AVOF I, II, III, and Opportunity Funds), strategic resources through its Nautilus community platform for portfolio leadership, and Compass as a company-building playbook. The firm has launched 92 startups, achieved 43 IPOs, and 39 M&A exits, with over 25 medicines made by portfolio companies.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • 25+ medicines developed by portfolio companies
  • +3 more outcomes

Companies that use Atlas Venture

Customer profile

Segments2 records

Ideal customer profiles2 records

Atlas Venture technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Atlas Venture partnerships and signals

Strategic signal

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Atlas Venture competitors and assessment

Company assessment

Direct peers

  • Flagship Pioneering: Flagship Pioneering is a direct peer - a Cambridge-based biotech company creation platform that builds breakthrough life sciences ventures from inception using an "origination" model closely analogous to Atlas's incubator approach. Both firms operate scientist-EIR partnerships to launch new biotech companies rather than purely funding external teams.
  • Third Rock Ventures: Third Rock Ventures is a direct peer - a Boston-based venture firm that builds biotech companies from inception by partnering with entrepreneurs and scientists, mirroring Atlas's seed-led company creation model. Both firms focus on launching and operating new biotech ventures rather than just providing capital.
  • ARCH Venture Partners: ARCH Venture Partners is a direct peer - one of the largest early-stage biotech VCs that co-invests alongside Atlas in deals like Kailera Therapeutics and nChroma Bio, with a comparable focus on creating companies from breakthrough university and biotech research.
  • Versant Ventures: Versant Ventures is a direct peer - a healthcare-focused VC that builds biotech companies through in-house incubation (e.g., Inception Sciences) similar to Atlas's EIR-driven model, investing across multiple fund vintages with comparable life sciences focus.
  • 5AM Ventures: 5AM Ventures is a direct peer - an early-stage life sciences VC firm with a hands-on company creation approach that has operated comparable fund vintages and portfolio strategies to Atlas, often co-investing in seed and Series A biotech rounds.
  • OrbiMed: OrbiMed is a direct peer - one of the largest healthcare-dedicated investment firms globally, participating in many of the same rounds as Atlas (Q32 Bio, etc.) with a broader life sciences mandate spanning venture, growth, and public equities.
  • RA Capital Management: RA Capital Management is a direct peer - a healthcare-focused crossover fund that co-leads many of Atlas's portfolio financings (Kinaset, TRIANA, Q32 Bio), offering a complementary late-stage and public-equity capability that overlaps with Atlas's biotech investing universe.
  • Foresite Capital: Foresite Capital is a direct peer - a healthcare and biotech-focused investment firm that has co-invested with Atlas and operates comparable fund vintages targeting therapeutic and biomedical innovation, often overlapping in syndicate participation.
  • Apple Tree Partners: Apple Tree Partners is a direct peer - a biotech-focused venture firm that builds companies through internal incubation, comparable to Atlas's model, and competes for similar life sciences talent and deal flow in the Northeast US ecosystem.

Broad incumbents

  • New Enterprise Associates (NEA): NEA is a broad incumbent - a large multi-stage venture firm with a significant healthcare and biotech practice that competes for similar deals and LPs, though its broader tech focus makes it less specialized than Atlas in biotech venture creation.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Atlas Venture social profiles

Digital presence

Atlas Venture financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Atlas Venture leadership team

Management profile

Number of profiles

Profiles23 records

Atlas Venture funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Atlas Venture M&A and investment

M&A and investment

M&A

Investments682 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Atlas Venture

What does Atlas Venture do?

Atlas Venture is a life sciences venture capital firm that creates, incubates, and invests in early-stage biotechnology companies through multiple dedicated funds. The firm partners shoulder-to-shoulder with Entrepreneurs-In-Residence and operators to build platform and product companies, providing capital, strategic guidance, and operational resources from seed through commercialization, and generating returns via management fees, carried interest, and equity stakes in portfolio exits.

Is Atlas Venture a public or private company?

Atlas Venture is a private company. It is classified as management employee owned and is currently operating.

When was Atlas Venture founded?

Atlas Venture was founded in 1992. It employs 101 to 250 people.

Where is Atlas Venture based?

Atlas Venture is headquartered in Cambridge, United States, in the North America region.

How does Atlas Venture make money?

Two revenue lines are on record. Fund Management is the primary driver. The others are portfolio Company Equity.

Who are Atlas Venture's main competitors?

Direct peers on record are Flagship Pioneering, Third Rock Ventures, ARCH Venture Partners, Versant Ventures, 5AM Ventures, OrbiMed, RA Capital Management, Foresite Capital and Apple Tree Partners. New Enterprise Associates (NEA) is listed as a broad incumbent.

Does Atlas Venture have an API?

No public API is recorded for Atlas Venture.

What industry is Atlas Venture in?

Atlas Venture's product category is Life Sciences Venture Capital. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of BPAHADAC, M&A Advisory (Buy-side/Sell-side). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Tracxn2026 Funding Rounds & List of InvestorsNimbus Therapeutics has raised multiple funding rounds from 2010 to 2023, with the most recent being a Series F in September 2023. The rounds include Series E, D, C, and earlier, with lead investors such as BVF Partners and Atlas Venture.Stock TitanSynlogic Agrees to Caldera Merger, $278M PlacementSynlogic, Inc. and Caldera Therapeutics, Inc. have entered into a definitive merger agreement to combine in an all-stock transaction, with the resulting company to operate as Caldera Therapeutics, Inc. and list on Nasdaq under the ticker symbol CALD. Caldera has secured a concurrent upsized private placement of approximately $278 million from a syndicate of healthcare institutional investors, including Bain Capital Life Sciences, TCGX, Atlas Venture, and others, to fund Phase 2 clinical trials of CLD-423 in ulcerative colitis and Crohn's disease through 2029. CLD-423 is a potential first-in-class bispecific antibody targeting TL1A and IL-23p19 pathways for inflammatory bowel disease and other immune-mediated diseases, currently completing Phase 1 trials in Australia.BioSpaceSynlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private PlacementSynlogic and Caldera Therapeutics announced a merger agreement to combine in an all-stock transaction, with the combined company operating as Caldera Therapeutics. Caldera secured a concurrent private placement of approximately $278 million to fund Phase 2 clinical trials, with cash runway projected into 2029. The deal is expected to close by early 2027.FierceBiotechEthyreal Bio manifests with $101M in pack of biotechs gunning for Amgen’s TepezzaEthyreal Bio has exited stealth with $101 million in series A and B funding from Atlas Venture and Medicxi Ventures to advance an anti-TSHR antibody (ETHY-001) for thyroid eye disease and Graves' disease, with a first-in-human trial scheduled to start this year. The Massachusetts-based biotech is positioning itself to compete with Amgen's blockbuster drug Tepezza, which holds FDA approval for thyroid eye disease, amid a crowded field of competitors including Viridian Therapeutics, whose FDA decision on veligrotug is expected this month. The company plans to present preclinical data on its subcutaneous autoinjector-administered antibody next week at the Endocrine Society's 2026 Annual Meeting.citybizEthyreal Bio Raises $101M as Investors Back New Approach to Graves’ and Thyroid Eye DiseaseEthyreal Bio, a Cambridge, Massachusetts-based biotech company, has emerged from stealth with $101 million in combined Series A and B financing to advance its ETHY-001 monoclonal antibody program targeting Graves' disease and thyroid eye disease. The funding round was co-led by Atlas Venture and Medicxi Ventures with participation from Avoro Capital, Nandi Life Sciences, and Checkpoint Capital, and the company plans to initiate first-in-human clinical trials in the second half of 2026. The therapy aims to address both conditions through a single mechanism-driven approach targeting the thyroid-stimulating hormone receptor, addressing a root cause that existing treatments for Graves' disease have not tackled in over 70 years.GlobeNewswireEthyreal Bio Emerges from Stealth with $101 Million in Financing to Advance ETHY-001, a Potentially Best-in-Class Anti-TSHR Antibody for Thyroid Eye Disease and Graves’ DiseaseEthyreal Bio launched publicly on June 10, 2026, with $101 million in combined Series A and Series B financing led by Atlas Venture, Medicxi Ventures, Avoro Capital, Nandi Life Sciences, and Checkpoint Capital to advance its lead program ETHY-001, a monoclonal antibody antagonist targeting the thyroid stimulating hormone receptor for Graves' disease and thyroid eye disease. The company plans to initiate first-in-human clinical trials in the second half of 2026 and will present preclinical data at the Endocrine Society's 2026 Annual Meeting in Chicago on June 15. ETHY-001 is designed for subcutaneous administration with half-life extension technology to enable infrequent dosing and addresses a significant unmet need, as existing treatments for Graves' disease do not treat or prevent thyroid eye disease.GenengnewsStockWatch: Agilent Shares Jump on Better than Expected Quarterly ResultsAgilent Technologies reported Q2 FY26 net income of $339 million, up 58% year-over-year, on revenue of $1.835 billion, beating analyst forecasts. Shares surged 17% to $135.42, and the company raised its FY26 revenue guidance to $7.39–$7.49 billion. Analysts raised price targets, citing AI-driven pharma demand and reshoring trends.Fastdata极数美国自身免疫及炎性疾病疗法开发商Q32 Bio获得5500万美元战略投资 – Fastdata极数Q32 Bio, a developer of autoimmune and inflammatory disease therapies, received a $55 million strategic investment led by BVF Partners, with participation from RA Capital Management, OrbiMed, and Atlas Venture. The company is developing biologics targeting the innate and adaptive immune systems for patients with severe conditions lacking effective treatments.PR NewswireQ32 Bio Announces $55 Million Private Placement FinancingQ32 Bio announced a private placement of approximately $55 million in common stock and pre-funded warrants, with 6,725,000 shares at $8.00 each and 150,000 warrants. The placement is expected to close on May 28, 2026, led by BVF Partners L.P. with Morgan Stanley as lead placement agent.ChinaventureJiangsu's richest man invests in the most expensive weight loss drug in history.Kailera, a GLP-1 weight loss drug developer, raised $625 million in its NASDAQ IPO, the largest biotech fundraising ever. The company's success stems from its 2024 partnership with Chinese firm HengRui Medicine, making China the biggest beneficiary.